Michelle Peeden
Family Medicine · Cincinnati, OHNPI 1972997047
Payments from drug & device makers
Across 310 payments — averaging $22.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Abbott$1K
- AstraZeneca$764
- Boehringer Ingelheim$682
- Novo Nordisk$393
- Lilly USA, LLC$342
- plus $3K from 28 others
What the payments were for
- Food & beverage$7,100100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 86 | $1,227 |
| Abbott | 28 | $1,018 |
| AstraZeneca | 21 | $764 |
| Boehringer Ingelheim | 21 | $682 |
| Novo Nordisk | 22 | $393 |
| Lilly USA, LLC | 21 | $342 |
| Johnson & Johnson | 6 | $304 |
| Dexcom, Inc. | 8 | $285 |
| Pfizer | 17 | $263 |
| GSK | 8 | $213 |
| Sanofi-aventis U.S. LLC | 7 | $182 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $175 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $152 |
| Novartis | 9 | $144 |
| Exact Sciences | 6 | $128 |
| Amgen | 3 | $117 |
| Lucid Diagnostics Inc. | 1 | $115 |
| Merck | 6 | $96 |
| Astellas Pharma US Inc | 4 | $86 |
| Axsome Therapeutics, Inc. | 3 | $79 |
| Bayer | 3 | $48 |
| Kowa Pharmaceuticals America, Inc. | 3 | $42 |
| Sunovion Pharmaceuticals Inc. | 3 | $38 |
| Almatica Pharma LLC | 2 | $33 |
| Sumitomo Pharma America, Inc. | 2 | $32 |
| Tolmar, Inc. | 2 | $28 |
| Viatris Specialty LLC | 1 | $21 |
| Corcept Therapeutics | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $17 |
| Currax Pharmaceuticals LLC | 1 | $12 |
| Acerus Pharmaceuticals Corporation | 1 | $12 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Shire North American Group Inc | 1 | $12 |
| Sanofi Pasteur Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$348
- FreeStyle Libre 2$292
- FREESTYLE LIBRE 3$282
- XARELTO$250
- BREZTRI$241
- AIRSUPRA$241
- JARDIANCE$232
- FASENRA$126
- NURTEC ODT$125
- XIFAXAN$125
- DEXCOM G6 TRANSMITTER$121
- TRELEGY ELLIPTA$115
- SOLIQUA 100/33$101
How this compares
$7,100 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 36 | $34,363 |
| EliquisApixaban | 37 | $28,414 |
| MounjaroTirzepatide | 22 | $26,836 |
| JanuviaSitagliptin Phosphate | 15 | $23,328 |
| JardianceEmpagliflozin | 27 | $21,880 |
| FarxigaDapagliflozin Propanediol | 15 | $20,709 |
| Novolog FlexpenInsulin Aspart | 12 | $3,029 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $2,950 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 74 | $1,959 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 11 | $1,879 |
| Atorvastatin Calcium | 224 | $1,555 |
| Ezetimibe | 34 | $1,473 |
| Gabapentin | 107 | $1,051 |
| Pregabalin | 25 | $890 |
| Pantoprazole Sodium | 67 | $880 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $393 | $34,36336 claims |
| PfizerEliquis | $263 | $28,41437 claims |
| Lilly USA, LLCMounjaro, Olanzapine | $342 | $27,44835 claims |
| MerckJanuvia | $96 | $23,32815 claims |
| Boehringer IngelheimJardiance | $682 | $21,88027 claims |
| AstraZenecaFarxiga | $764 | $20,70915 claims |
| AbbVieSynthroid | $1,227 | $85432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Cincinnati
- Michael ButcherCincinnati$18.3M
- Paul NugentCincinnati$4.9M
- Rajesh DavitCincinnati$2M
- Michael HeileCincinnati$272K
- Michael NossCincinnati$265K
- Amy MechleyCincinnati$120K
- Melissa SchroerCincinnati$116K
- William CoxCincinnati$52K
- Frank PerrinoCincinnati$49K
- Sean LyndCincinnati$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.